Abstracts tagged "SLE"

Abstract Number: 1121 • 2016 ACR/ARHP Annual Meeting
IFN Regulatory Factor-5 Signaling Increases IFN-Gamma Production and Suppresses IL-2 Production from CD4+ T Cells, and Controls IgG Production in B Cells
Kei Yasuda¹, Prachi Shukla², Ramon G. Bonegio¹ and Ian Rifkin¹, ¹Renal Section, Boston Univ Schl of Med, Boston, MA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies of human genetics and mouse models have shown that interferon regulatory factor-5 (IRF5) is associated with the development of autoimmune disease. However,…
Abstract Number: 1775 • 2016 ACR/ARHP Annual Meeting
Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Shawn Kwatra¹, Michelle Petri² and Wei Fu³, ¹Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
ACR Abstract Authors: Shawn G. Kwatra1, Wei Fu2, Michelle Petri2 1Department of Dermatology, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD Title:…
Abstract Number: 2451 • 2016 ACR/ARHP Annual Meeting
Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus
Yonit Sterba¹, Tamara Tanner² and Dawn Wahezi¹, ¹Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, The Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: The onset of childhood systemic lupus erythematosus (cSLE) most frequently occurs after age 12. Studies in adolescents with cSLE suggest that ovarian dysfunction may…
Abstract Number: 2871 • 2016 ACR/ARHP Annual Meeting
Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Teresa Aberle¹, Virginia C. Roberts¹, Joel M. Guthridge³, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael Weisman⁶, Mariko Ishimori⁶, Daniel J Wallace⁷, David Karp⁸, Kathy L. Sivils¹, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. Blood relatives (Rel) of lupus patients…
Abstract Number: 3242 • 2016 ACR/ARHP Annual Meeting
Identification and Functional Characterization of TNIP1 Causal Variants Associated with Systemic Lupus Erythematosus
Satish Pasula¹, Mandi Wiley¹, Ying-yu Wu¹, Ajay Nair¹, Jaanam Gopalakrishnan² and Patrick M. Gaffney¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production and dysregulated interferon responses. Genome-wide association studies (GWAS) have identified more…
Abstract Number: 770 • 2016 ACR/ARHP Annual Meeting
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Jarrat Jordan¹, Matteo Cesaroni¹, Jessica Schreiter¹, Chichi Huang², Tanesha Cash-Mason³, Marc Chevrier¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Biologics Research, Janssen Research and Development, LLC., Spring House, PA, ³Cardiovascular and Metabolism Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…
Abstract Number: 1171 • 2016 ACR/ARHP Annual Meeting
Obesity and the Risk of Systemic Lupus Erythematosus in the Nurses’ Health Studies
Sara K. Tedeschi¹, Medha Barbhaiya¹, Bing Lu¹, Susan Malspeis², Jeffrey A. Sparks², Elizabeth W. Karlson¹, Walter C. Willett³ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Obesity has become alarmingly common over the past four decades in the U.S., with a notable rise in obesity prevalence starting in the late…
Abstract Number: 1789 • 2016 ACR/ARHP Annual Meeting
Herpetic Viruses in Lupus
Teja Kapoor¹, Pooja Mahadeshwar², Barkha Bhandari³, Jianhua Li⁴, Joan Bathon⁵, Samantha Nguyen⁶ and Anca D. Askanase⁷, ¹Medicine, Division of Rheumatology, Columbia University Medical Center, New York, NY, ²George Washington University Hospital, Washington, DC, ³American University of Antigua, Antigua Guatemala, Antigua and Barbuda, ⁴Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁶Columbia University Medical Center, NY, NY, ⁷Medicine, Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: This is a retrospective cohort study evaluating the prevalence of VZV and HSV in SLE patients hospitalized at Columbia University Medical Center-New York…
Abstract Number: 2782 • 2016 ACR/ARHP Annual Meeting
Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Kazuhisa Nozawa¹, Yuko Matsuki², Ken Yamaji³, Naoto Tamura⁴ and Yoshinari Takasaki³, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Rheumatology, Juntendo University, Tokyo, Japan
Background/Purpose: Lupus nephritis (LN) is one of the main causes of morbidity and mortality in SLE. Although a combination therapy using steroids and immunosuppressant…
Abstract Number: 2872 • 2016 ACR/ARHP Annual Meeting
SLE Subjects Express High Levels of Intracellular Interferon-β That Acts in an Autocrine Fashion to Promote Survival of Transitional Stage B Cells
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Jun Li⁶, Ignacio Sanz⁷, W. Winn Chatham⁸, Hui-Chen Hsu² and John D. Mountz⁹, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ⁸Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Upregulation of interferon-β (IFNβ) is an important step in promoting maturation and survival of B cells. Secretion and autocrine action of IFNβ requires assembly…
Abstract Number: 3243 • 2016 ACR/ARHP Annual Meeting
Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity
Doua F. Azzouz¹, Lelise Getu², Celine Anquetil¹, Jill P. Buyon³ and Gregg J. Silverman³, ¹Medicine, NYU School of Medicine, New York, NY, ²Department of Medicine, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY
Background/Purpose: SLE is a complex multifactorial systemic autoimmune disease, which has been attributed to poorly understood interactions between genetic and environmental factors. Recent reports have…
Abstract Number: 771 • 2016 ACR/ARHP Annual Meeting
Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE
Hisaji Oshima¹, Masaki Iwasaki¹, Ikuko Tanaka², Misako Higashida³, Mari Ushikubo⁴, Eriko Takei⁵, Kumiko Akiya³ and Keisuke Izumi⁶, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²NAGOYA Rheumatology Clinic, Nagoya, Japan, ³Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ⁴Department of Connective Tissue Disease, National Tokyo Medical Center, Tokyo, Japan, ⁵Connective tissue disease, National Tokyo Medical Center, Tokyo, Japan, ⁶Connective Tissue Dseases, National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Several cross-sectional studies have shown a progression of atherosclerosis in SLE was associated with activities of SLE but not with glucocorticoid therapy. However, a…
Abstract Number: 1182 • 2016 ACR/ARHP Annual Meeting
Opiod Use and Death in Chronic Pain Patients with Systemic Lupus Erythematosis
Romy Cabacungan¹, Clifford Qualls², Wilmer Sibbitt Jr.¹, Timothy Moore¹, Luis Salayandia¹, Roderick Fields³, Suzanne Emil¹, Monthida Fangtham¹, Konstantin Konstantinov⁴, Tej Bhavsar¹ and Arthur Bankhurst⁵, ¹Rheumatology, University of New Mexico, Albuquerque, NM, ²Biostatistics, UNM, Albuquerque, NM, ³Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM, ⁴1 University Of New Mexico, University of New Mexico, Albuquerque, NM, ⁵Rheumatology, University of NM Medical Center, Albuquerque, NM
Background/Purpose: Chronic pain is one of the most common symptoms reported in patients with SLE. Treating pain in these individuals can be complex and…
Abstract Number: 1798 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review
Sara Hussein¹, Manon Suitner¹, Alexandra Baril-Dionne¹, Mihaela Luminita Popescu¹, Nancy Santesso², Stephanie O. Keeling³, Janet E. Pope⁴, Aurore Fifi-Mah⁵ and Josiane Bourré-Tessier¹, ¹Université de Montréal, Montreal, QC, Canada, ²McMaster University, Hamilton, ON, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Non-traumatic osteonecrosis (ON) is a well-recognized complication in systemic lupus erythematosus (SLE). The reported symptomatic ON prevalence is 10-15% and as high as 44%…
Abstract Number: 2785 • 2016 ACR/ARHP Annual Meeting
Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)
Garth Ringheim¹, Jolanta Kosek², Lori Capone³, Mary Adams^4,5, Eun Mi Hur⁴ and Peter H. Schafer⁵, ¹86 Morris Avenue, Celgene Corporation, Summit, NJ, ²Translational Development, Celgene Corporation, Summit, NJ, ³Celgene Corporation, Summit, NJ, ⁴Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: CC-292 and CC-90008 are covalent Btk/Tec family kinase inhibitors that block Btk activity by binding with high affinity to the adenosine triphosphate (ATP) binding…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].